Metrics as of 10/15/2026, 05:56 AM (Berlin time), refresh in progress.
Avicanna Stock
Avicanna Inc.
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Canada
- CEO
- Aras Azadian Mba
- Employees
- 112
- Market cap
- $13 M
- IPO
- 18/07/2019
Avicanna Inc., a biopharmaceutical firm headquartered in Toronto, Canada, and founded in 2016, is actively engaged in the research, development, and commercialization of scientifically validated products for both global medical and consumer health markets. The company's comprehensive scientific framework encompasses…
Avicanna stock: price history
1D
-13.0%
1W
-9.1%
1M
-16.7%
6M
-33.3%
YTD
-55.6%
1Y
-63.0%
2Y
-66.7%
5Y
-87.3%
10Y
–
Next earnings date
Next earnings date
13/11/2026 (in 27 days)
Volatility around earnings
~3% stronger price swings than usual
Ask the agents about Avicanna
Avicanna stock metrics
P/E
-3.09
P/B
2.74
EV/EBITDA
-4.12
RETURN ON EQUITY
-22.2%
NET MARGIN
-18.1%
DEBT/EQUITY
0.04
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
78.6%
FLOAT SHARES
105,562,260
AVG. DAILY VOLUME (30D)
126,087
Comparable stocks
Frequently asked questions about Avicanna stock
What does Avicanna do?
Avicanna Inc. is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in Canada.
The CEO is Aras Azadian Mba, the company employs around 112 people.
The IPO was on 18/07/2019; the stock trades on TSX under the ticker AVCN.TO.
When does Avicanna report next?
The next earnings date is 13/11/2026.
Around past earnings, price swings were roughly 3% stronger than usual.
Does Avicanna pay a dividend?
No, Avicanna currently does not pay a dividend.
Which stocks are comparable to Avicanna?
Comparable stocks include Merck, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries, Zoetis, Sandoz Group, Viatris, Lantheus Holdings and Amneal Pharmaceuticals.
How can I get Avicanna stock analyzed?
Clicking "Analyze stock" lets five strategies assess Avicanna against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.